Pathways of chemotherapy resistance in castration-resistant prostate cancer

Endocrine-Related Cancer

Volumn 18, Issue 4, 2011, Pages

  Mahon, Kate L ^a,b,c   Henshall, Susan M ^c   Sutherland, Robert L ^c   Horvath, Lisa G ^a,b,c  

^a SYDNEY CANCER CENTRE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; AEG 35156; BCL2 RELATED PROTEIN A1; BEVACIZUMAB; CASPASE 3; CLUSTERIN; CUSTIRSEN; CYTOCHROME C; DOCETAXEL; GATAPARSEN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK TRANSCRIPTION FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; ISOSORBIDE; LENALIDOMIDE; OBLIMERSEN; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN MDM2; PROTEIN P53; RETASPIMYCIN; TANESPIMYCIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; B CELL LEUKEMIA; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; DRUG TOLERABILITY; ENZYME ACTIVATION; HORMONAL THERAPY; HUMAN; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 80052182605     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0343     Document Type: Review

References (190)

1. AIHW (Australian Institute of Health and Welfare) and AACR (Australasian Association of Cancer Registries) 2008 Cancer in Australia: an overview. Cat. no. CAN42. Canberra, Australia: AIHW.
2. Altmann KH 2005 Recent developments in the chemical biology of epothilones. Current Pharmaceutical Design 11 1595-1613. (doi:10.2174/ 1381612053764715)
3. Amantana A, London CA, Iversen PL & Devi GR 2004 X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Molecular Cancer Therapeutics 3 699-707. (Pubitemid 39193751)
4. Aragon-Ching JB & Dahut WL 2008 The role of angiogenesis inhibitors in prostate cancer. Cancer Journal 14 20-25. (doi:10.1097/PPO.0b013e318161c014)
5. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB & Lokeshwar BL 2007 Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Research 67 6854-6862. (doi:10.1158/0008-5472.CAN-07-1162)
6. Banerji U 2009 Heat shock protein 90 as a drug target: some like it hot. Clinical Cancer Research 15 9-14. (doi:10. 1158/1078-0432.CCR-08-0132)
7. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M, Liu T, Smith D, Kuffner T, Pankhurst GJ et al. 2005 The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Research 65 2330-2336. (doi:10.1158/0008-5472.CAN-04-3827)
8. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M & Breit SN 2006 Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Research 66 4983-4986. (doi:10.1158/0008-5472.CAN-05-4067)
9. Beardsley EK, Saad F, Eigl B, Venner P, Hotte S, Winquist E, Ko YJ, Sridhar SS & Chi KN 2009 A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel.ASCOAnnual meeting abstract. Journal of Clinical Oncology 27 (15S) abstract 5139.
10. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD et al. 2008 C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 112 2377-2383. (doi:10.1002/cncr.23461)
11. Bellone M, Mondino A & Corti A 2008 Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends in Immunology 29 235-241. (doi:10.1016/j.it.2008.02.003)
12. Bond GL, Hu W & Levine AJ 2005 MDM2 is a central node in the p53 pathway: 12 years and counting. Current Cancer Drug Targets 5 3-8. (Pubitemid 40321795)
13. Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P &Ferrara N 1998 Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35 1-10. (Pubitemid 28158631)
14. Borsellino N, Belldegrun A & Bonavida B 1995 Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Research 55 4633-4639.
15. Bradshaw DM & Arceci RJ 1998 Clinical relevance of transmembrane drug efflux as a mechanism of multi-drug resistance. Journal of Clinical Oncology 16 3674-3690. (Pubitemid 28506783)
16. Brat DJ, Bellail AC & Van Meir EG 2005 The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology 7 122-133. (doi:10.1215/S1152851704001061)
17. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM et al. 2006 Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clinical Cancer Research 12 89-96. (doi:10.1158/1078-0432.CCR-05-1331)
18. Castellano DE, Gonzalez-Larriba J, Anton-Aparicio LM, Cassinello J, Grande Pulido E, Esteban E 2010 Clinical, serological, and radiographic benefit with sunitinib as a single agent in metastatic chemotherapy-resistant and hormone-refractory prostate cancer (HRPC) patients. In ASCO 2010 Genitourinary Cancers Symposium, abstract 229.
19. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA et al. 2007 The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26 2822-2832. (doi:10.1038/sj.onc.1210097)
20. Cetnar JP, Rosen MA, Vaughn DJ, Haas NB, Troxel AB, Song H, Adluru G, Flaherty KT, O'Dwyer PJ & Amaravadi RK 2009 Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). ASCO Meeting. Journal of Clinical Oncology 27 abstract e16055.
21. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, PollakM & Giovannucci E 2002 Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Journal of National Cancer Institute 94 1099-1106. (doi:10.1093/jnci/94.14.1099)
22. Chen T, Wang LH & Farrar WL 2000 Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Research 60 2132-2135. (Pubitemid 30225173)
23. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, D'Aloisio S & Tolcher AW 2001 A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormonerefractory prostate cancer. Clinical Cancer Research 7 3920-3927.
24. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D & Gleave ME 2005a A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. Journal of National Cancer Institute 97 1287-1296. (doi:10.1093/jnci/dji252)
25. Chi KN, Eisenhauer E, Siu L, Hirte H, Hotte SJ, Chia S, Knox J, Guns E, Powers J & Gleave ME 2005b A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154. Journal of Clinical Oncology 23 (16S) abstract 3085.
26. Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B & Visakorpi T 2009a Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. European Urology 56 594-605. (doi:10.1016/j.eururo.2009.06.027)
27. Chi KN, Hotte SJ, Yu E, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Eisenhauer E et al. 2009b Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. ASCO Annual meeting abstract. Journal of Clinical Oncology 27 (15S) abstract 5012.
28. Chiou SK, Jones MK & Tarnawski AS 2003 Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Medical Science Monitor 9 PI25-PI29.
29. Chopra DP, Menard RE, Januszewski J & Mattingly RR 2004 TNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Letters 203 145-154. (doi:10.1016/j.canlet.2003.09.016)
30. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M &Cheng AL 2002 Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochemical Pharmacology 63 1709-1716.
31. Chung TD, Yu JJ, Spiotto MT, Bartkowski M & Simons JW 1999 Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38 199-207. (Pubitemid 29054936)
32. Culig Z, Oh SJ, Santer FR, Puhr M, Steiner H & Hobisch A 2009 Effects of sorafenib on proliferation of hormonesensitive and hormone-insensitive prostate cancer cells. ASCO Meeting. Journal of Clinical Oncology 27 abstract e16092.
33. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M & Iacobelli S 2008 Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Letters 270 229-233. (doi:10.1016/j.canlet.2008.05.007)
34. Dahut WL, Scripture CD, Posadas EM, Wu S, Arlen PM, Gulley JL, Wright J, Chen CC, Jones E & Figg WD 2006 Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. ASCO Meeting. Journal of Clinical Oncology 24 abstract 4506.
35. Dash R, Richards JE, Su ZZ, Bhutia SK, Azab B, Rahmani M, Dasmahapatra G, Yacoub A, Dent P,Dmitriev IP et al. 2010 Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Research 70 5034-5045. (doi:10.1158/00008-5472.CAN-10-0563)
36. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J et al. 2009 Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. Journal of Clinical Oncology 27 1660-1666. (doi:10.1200/JCO.2008.19.5677)
37. De Bono JS, Fizazi K, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen J, Hudes GR 2010a Randomized phase II study of CNTO 328 (C), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone (M) versusMalone in metastatic castrationresistant prostate cancer (CRPC). In ASCO 2010 Genitourinary Cancers Symposium, abstract 86.
38. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JH, Shen L, Matthews P, Sartor AO & For the TROPIC Investigators 2010b Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). Journal of Clinical Oncology 28 4508.
39. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L et al. 2010c Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 1147-1154. (doi:10.1016/S0140-6736(10)61389-X)
40. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB & Nelson WG 2007 Inflammation in prostate carcinogenesis. Nature Reviews Cancer 7 256-269. (doi:10.1038/nrc2090)
41. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS & Reed JC 1998 IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO Journal 17 2215-2223. (doi:10.1093/emboj/17.8.2215)
42. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, Imbimbo C, Perdona S, Giordano A & Giuliano M 2008 Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. European Urology 54 1089-1096. (doi:10.1016/j.eururo.2008.01.082)
43. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campas C &Dang L 2006 Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clinical Cancer Research 12 5578-5586. (doi:10.1158/1078-0432.CCR-05-2767)
44. Domingo-Domenech J, Martinez-Fernandez A, Garcia-Albeniz X, Fernandez P, Filella X, Gascon P & Mellado B 2007 Correlation of serum interleukin-6 (IL-6) levels with immunohistochemical p65/nuclear factor-{kappa}B (NF-{kappa}B) expression and prediction of the clinical outcome of hormone-independent prostate cancer patients (HIPC) treated with docetaxel (D). ASCO Annual meeting abstract. Journal of Clinical Oncology 25 (18S) abstract 5075.
45. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW & Smith MR 2009 Phase II study of sunitinib in men with advanced prostate cancer. Annals of Oncology 20 913-920. (doi:10.1093/annonc/mdp111)
46. Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, Shiels H, Hardwick JM & Thompson CB 1996 A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO Journal 15 2685-2694. (Pubitemid 26176246)
47. Epstein RJ 2007 VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Reviews 26 443-452. (doi:10.1007/s10555-007- 9071-1)
48. Ferlay J Bray F, Pisani P, Parkin D 2004 GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base, vol 5.
49. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA & Pluda J 2001a A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Seminars in Oncology 28 62-66. (Pubitemid 32947554)
50. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK et al. 2001b A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clinical Cancer Research 7 1888-1893. (Pubitemid 32994822)
51. Figg WD, Retter A, Steinberg SM & Dahut WL 2005 In reply. Journal of Clinical Oncology 23 2113-2114.
52. Figueroa JA, De Raad S, Tadlock L, Speights VO & Rinehart JJ 1998 Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. Journal of Oncology 159 1379-1383. (Pubitemid 28172839)
53. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI & Agus DB 2002 Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clinical Cancer Research 8 3226-3231. (Pubitemid 35155035)
54. Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA et al. 2004 Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clinical Cancer Research 10 7220-7228. (doi:10.1158/1078-0432.CCR-04-0452)
55. Gabai VL, Budagova KR & Sherman MY 2005 Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 24 3328-3338. (doi:10.1038/sj.onc.1208495)
56. Gelmon KA, Latreille J, Tolcher A, Genier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A et al. 2000 Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol 18 4098-4108. (Pubitemid 32038402)
57. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ & Kantoff PW 2001 Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clinical Cancer Research 7 1932-1936. (Pubitemid 32994827)
58. Gillison TL, Appleman LJ, Friedland DM, Evans TL, Lara PN, Gooding WE, Lenzner DE, Strausser HM, Gingrich JR & Chatta GS 2009 Docetaxel and imatinib every 21 days for castration resistant prostate cancer: a phase II trial. ASCO Annual meeting abstract. Journal of Clinical Oncology 27 (15S) abstract e16086.
59. Gleave M, Miyake H & Chi K 2005 Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemotherapy and Pharmacology 56 (Supplement 1) 47-57. (doi:10.1007/s00280-005- 0098-0)
60. Gomez-Pinillos A, Ballard H, Shelton G, Reilly MM, Chachoua A, Taneja S & Ferrari AC 2009 Sequential and intermittent docetaxel (D) and imatinib (Im) in hormone-refractory prostate cancer patients (NYU 04-47). ASCO Annual meeting abstract. Journal of Clinical Oncology 27 (15S) abstract e16108.
61. Gross ME, Soscia J, Sakowsky S, Castellanos O & Agus DB 2009 Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC). ASCO Annual meeting abstract. Journal of Clinical Oncology 27 (15S) abstract 5154.
62. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB & Hidalgo M 2002 Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Research 62 6141-6145. (Pubitemid 35244463)
63. Guerin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM & Milano G 2008 Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. Journal of Cancer Research and Clinical Oncology 134 51-57. (doi:10.1007/s00432-007-0247-4)
64. Haldar S, Chintapalli J & Croce CM 1996 Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Research 56 1253-1255. (Pubitemid 26080965)
65. Haupt Y, Maya R, Kazaz A & Oren M 1997 Mdm2 promotes the rapid degradation of p53. Nature 387 296-299. (doi:10.1038/387296a0)
66. Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S & Manome Y 2005 Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 65 10-19. (doi:10.1002/pros.20232)
67. Heldin CH, Rubin K, Pietras K & Ostman A 2004 High interstitial fluid pressure - an obstacle in cancer therapy. Nature Reviews Cancer 4 806-813. (doi:10.1038/nrc1456)
68. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H & Culig Z 1998 Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Research 58 4640-4645. (Pubitemid 28480629)
69. Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, Chinnaiyan AM & Rubin MA 2004 Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 6 503-512. (Pubitemid 39411086)
70. Honda R, Tanaka H & Yasuda H 1997 Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Letters 420 25-27. (doi:10.1016/S0014- 5793(97)01480-4)
71. Hour T-C, Chen J, Huang C-Y, Guan J-Y, Lu S-H & Pu Y-S 2002 Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. Prostate 51 211-218. (doi:10.1002/pros.10089)
72. Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, GarzottoM&Nelson PS 2007 Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clinical Cancer Research 13 5825-5833. (doi:10.1158/1078-0432.CCR-07-1037)
73. Hudes G, Tagawa S, Whang Y, Qi M, Qin X, Puchalski T, Prabhakar U, O'Brien K & Eisenberger M 2009 A phase I study of CNTO328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel in subjects with metastatic castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology 27 5063.
74. Hussain M, Tangen CM, Lara PN Jr, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA& Crawford ED 2005 Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapynaive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial SO111. J Clin Oncol 23 8724-8729. (doi:10.1200/JCO.2005.02.4448)
75. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS & Johri AR 2009 Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Annals of Oncology 20 492-497. (doi:10.1093/annonc/mdn665)
76. Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K & Fumoleau PA 2008 A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. Journal of Clinical Oncology 26 3599.
77. Jain RK 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 58-62. (doi:10.1126/science.1104819)
78. Jemal A, Siegel R, Ward E, Hao Y, Xu J & Thun MJ 2009 Cancer statistics, 2009. CA: A Cancer Journal for Clinicians 59 225-249. (doi:10.3322/caac.20006)
79. Kamath K, Wilson L, Cabral F & Jordan MA 2005 BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. Journal of Biological Chemistry 280 12902-12907. (doi:10.1074/jbc.M414477200)
80. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP & Vogelzang NJ 1999 Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal of Clinical Oncology 17 2506-2513. (Pubitemid 29368252)
81. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk JP III, Small EJ et al. 2010 A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. ASCO meeting abstract. Journal of Clinical Oncology 28 (18S) abstract LBA4511.
82. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X et al. 2006 Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. Journal of National Cancer Institute 98 783-793. (doi:10.1093/jnci/djj211)
83. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S & Reed JC 1996 Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. American Journal of Pathology 148 1567-1576. (Pubitemid 26135897)
84. Kubler H, Van Randenborgh H, Treiber U, Lehmer A, Wagenpfeil S, Hartung R & Paul R 2004 Combined application of imatinib and standard chemotherapeutics results in additive cytotoxic effects in human prostate cancer cell lines. ASCO Annual meeting abstract. Journal of Clinical Oncology 22 (14S) abstract 4737.
85. LaCasse EC, Baird S, Korneluk RG & MacKenzie AE 1998 The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 3247-3259. (Pubitemid 29043977)
86. Lane DP 1992 Cancer. p53, guardian of the genome. Nature 358 15-16. (doi:10.1038/358015a0)
87. Larkin JMG & Kaye SB 2006 Epothilones in the treatment of cancer. Expert Opinion on Investigational Drugs 15 691-702. (doi:10.1517/13543784.15.6. 691)
88. Lebedeva I, Rando R, Ojwang J, Cossum P & Stein CA 2000 Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Research 60 6052-6060.
89. Lee JT Jr, Steelman LS & McCubrey JA 2004 Phosphatidylinositol 30-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Research 64 8397-8404. (doi:10.1158/0008-5472.CAN-04-1612)
90. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS & McCubrey JA 2008 Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 7 1745-1762. (Pubitemid 351988740)
91. Leonetti C, Biroccio A, D'Angelo C, Semple SC, ScarsellaM & Zupi G 2007 Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate 67 1475-1485. (doi:10.1002/pros.20636)
92. Leskov KS, Klokov DY, Li J, Kinsella TJ & Boothman DA 2003 Synthesis and functional analyses of nuclear clusterin, a cell death protein. Journal of Biological Chemistry 278 11590-11600. (doi:10.1074/jbc.M209233200)
93. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O & Sarkar FH 2005 Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Research 65 6934-6942. (doi:10.1158/0008-5472.CAN-04-4604)
94. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A et al. 1996 Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 379 349-353. (doi:10.1038/379349a0)
95. Lokiec FM, Brain EG, Faivre S, Armand J-P, Gillotin C, Boissaye P, Marty M & Raymond E 2003 Docetaxel (D) and epirubicin (E) pharmacokinetic (PK) results in a phase I combination study with the novel oral p-glycoprotein (P-gp) inhibitor elacridar (GF120918) in patients (pts) with locally advanced or metastatic cancer. MDRF1002 study. Proceedings of the American Society of Clinical Oncology 22 abstract 614.
96. Luduena RF 1998 Multiple forms of tubulin: different gene products and covalent modifications. International Review of Cytology 178 207-275. (doi:10.1016/S0074-7696(08)62138-5)
97. MacVicar GR, Greco A, Reeves J, Maleski J, Holmlund J & Leopold L 2009 An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology 27 5062.
98. Makarovskiy AN, Siryaporn E, Hixson DC & Akerley W 2002 Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cellular and Molecular Life Sciences 59 1198-1211. (doi:10.1007/s00018-002-8498-3)
99. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR & Hayes DF 2004 A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Annals of Oncology 15 1274-1283. (doi:10.1093/annonc/mdh317)
100. Mathew P, Thall PF, Johnson MM, Oh WK, Meluch AA, Morris MJ, Troncoso P, Bucana CD, Fidler IJ &Logothetis CJ 2006 Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). ASCO Annual meeting abstract. Journal of Clinical Oncology 24 (18S) abstract 4562.
101. Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee YC, Logothetis CJ et al. 2008 Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. British Journal of Cancer 99 1426-1432. (doi:10.1038/sj.bjc.6604706)
102. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG &Waugh DJ 2007 HIF-1 and NF-kappaB-mediated up-regulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 26 7333-7345. (doi:10.1038/sj.onc.1210536)
103. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM & Campbell ML 1992 Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Research 52 6940-6944. (Pubitemid 23006303)
104. Melnyk O, Zimmerman M, Kim KJ & Shuman M 1999 Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. Journal of Urology 161 960-963. (Pubitemid 29422416)
105. Meric-Bernstam F & Gonzalez-Angulo AM 2009 Targeting the mTOR signaling network for cancer therapy. Journal of Clinical Oncology 27 2278-2287. (doi:10.1200/JCO.2008.20.0766)
106. Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K et al. 2009 Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clinical Cancer Research 15 723-730. (doi:10.1158/1078-0432.CCR-08-0596)
107. Miyake H, Tolcher A & Gleave ME 2000a Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. Journal of National Cancer Institute 92 34-41. (doi:10.1093/jnci/92.1.34)
108. Miyake H, Chi KN & Gleave ME 2000b Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clinical Cancer Research 6 1655-1663. (Pubitemid 30305057)
109. Miyake H, Monia BP & Gleave ME 2000c Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. International Journal of Cancer 86 855-862. (Pubitemid 30350202)
110. Miyake H, Nelson C, Rennie PS & Gleave ME 2000d Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Research 60 2547-2554.
111. Miyake H, Nelson C, Rennie PS & Gleave ME 2000e Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141 2257-2265. (doi:10.1210/en.141.6.2257)
112. Mizutani K, Matsumoto K, Hasegawa N, Deguchi T &Nozawa Y 2006 Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells. Experimental Oncology 28 209-215. (Pubitemid 44735911)
113. Momand J, Jung D, Wilczynski S & Niland J 1998 The MDM2 gene amplification database. Nucleic Acids Research 26 3453-3459. (Pubitemid 28347214)
114. Montgomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R & Stahl WL 2005 Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate 65 141-150. (doi:10.1002/pros. 20246)
115. Montgomery B, Lin D, Ryan C, GarzottoM& Beer TM 2006 Diethylstilbestrol and docetaxel: a phase II study in patients with metastatic, androgen independent prostate cancer. ASCO Annual meeting abstract. Journal of Clinical Oncology 24 (18S) abstract 4627.
116. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M et al. 2002 Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clinical Cancer Research 8 679-683. (Pubitemid 34742094)
117. Morris MJ, Cordon-Cardo C, Kelly WK, Slovin SF, Siedlecki K, Regan KP, DiPaola RS, Rafi M, Rosen N & Scher HI 2005 Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Applied Immunohistochemistry & Molecular Morphology 13 6-13. (Pubitemid 40283796)
118. Moss RA, Shelton G, Melia J, Mohike SG, Petrylak DP 2007 A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). ASCO Prostate Cancer Symposium. abstract 89.
119. Musquire LA, Ramalingam S, Egorin MJ, Sikorski RP, Chatta GS, Ramanathan RK, Friedland D, Potter D, Ivy SP & Belani CP 2007 Phase I and pharmacokinetic (PK) study of 17-allylamino-17 demethoxygeldanamycin (17-AAG) in combination with weekly paclitaxel for advanced solid malignancies. ASCO Annual meeting abstract. Journal of Clinical Oncology 25 (18S) abstract 14028.
120. Nabhan C, Tolzien K, Lestingi TM, Kelby SK, Galvez AG, Bitran JD 2010 Activity of sorafenib (SOR) in chemotherapy-failure castration-resistant prostate cancer (CRPC). In ASCO Genitourinary Cancers Symposium, abstract 233.
121. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M et al. 2007 YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Research 67 8014-8021. (doi:10.1158/0008-5472.CAN-07-1343)
122. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ et al. 2001 Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemotherapy and Pharmacology 48 319-326. (Pubitemid 32835357)
123. Ning YM, Arlen PM, Gulley JL, Stein WD, Fojo AT, Latham L, Wright JJ, Parnes H, Figg WD & Dahut WL 2008 Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). ASCO Annual meeting abstract. Journal of Clinical Oncology 26 (15S) abstract 5000.
124. Nomura T, Mimata H, Takeuchi Y, Yamamoto H, Miyamoto E & Nomura Y 2003 The X-linked inhibitor of apoptosis protein inhibits taxol-induced apoptosis in LNCaP cells. Urological Research 31 37-44. (doi:10.1007/s00240-003- 0300-y)
125. Oh WK, Stadler WM, Srinivas S, Chu F, Bubley G, Quigley M, Goddard J, Dunbar J, Grayzel D, Ross RW 2009 A single arm phase II trial of IPI-504 in patients with castration resistant prostate cancer (CRPC). In ASCO Genitourinary Cancers Symposium. abstract 219.
126. Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, Zhong B, Pow-Sang J, Yeatman T & Djeu JY 2006 Novel role of stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25 6113-6122. (doi:10.1038/sj.onc.1209632)
127. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F & de la Taille A 2007 The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World Journal of Urology 25 477-489. (doi:10.1007/s00345-007-0175-6)
128. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M et al. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine 351 1513-1520. (doi:10.1056/ NEJMoa041318)
129. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G & Klocker H 2004 Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 58 259-268. (doi:10.1002/pros.10332)
130. Picus J, Halabi S, Rini B, Vogelzang N, Whang Y, Kaplan E, Kelly W & Small E 2003 The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proceedings of the American Society of Clinical Oncology 22 abstract 1578.
131. Pinski JK, Goldman B, Dorff T, Mack P, Lara P Jr, van Veldhuizen P, Quinn D, Hussain MH & Thompson IM 2009 SWOG S0354: a phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration-resistant prostate cancer (CRPC). ASCO Meeting. Journal of Clinical Oncology 27 abstract 5143.
132. Poiesz B, Reeves J, McNulty W, Maleski J, Holmlund J & Leopold L 2009 Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. Journal of Clinical Oncology 27 5145.
133. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M & Ferrara N 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research 57 4593-4599. (Pubitemid 27441066)
134. Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK & Kuo ML 2004 Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 60 120-129. (doi:10.1002/pros.20057)
135. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS &Buttyan R 1995 Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Research 55 4438-4445.
136. Rago RP, Einstein A Jr, Lush R, Beer TM, Ko Y-J, Henner WD, Bubley G, Merica EA, Garg V, Ette E et al. 2003 Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology 51 297-305. (doi:10.1007/s00280-003-0573-4)
137. Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D & Sakr WA 2009 3,3′-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Research 69 4468-4475. (doi:10.1158/0008-5472.CAN-08-4423)
138. Ramalingam SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, Lagattuta TF, Chatta GS, Friedland DM, Stoller RG, Potter DM et al. 2008 A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clinical Cancer Research 14 3456-3461. (doi:10.1158/1078-0432.CCR-07-5088)
139. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW &Hudes GR 1998 Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. British Journal of Cancer 77 562-566.
140. Reese DM, Fratesi P, Corry M, Novotny W, Holmgren E &Small EJ 2001 A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. The Prostate Journal 3 65-70.
141. Ren A, Yan G, You B & Sun J 2008 Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Research 68 2266-2274. (doi:10.1158/0008-5472.CAN- 07-6248)
142. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K & Gleave M 2004 Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Research 64 6595-6602. (doi:10.1158/0008-5472.CAN-03-3998)
143. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D & Small EJ 2007 Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110 556-563. (doi:10.1002/cncr.22811)
144. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL et al. 2009 Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Journal of Clinical Oncology 27 2772-2778. (doi:10.1200/JCO.2008.19. 8002)
145. Saad F, Hotte SJ, North SA, Eigl BJ, Chi KN, Czaykowski P, Polllak M, Wood L & Winquist E 2008 A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. Journal of Clinical Oncology 26 5002.
146. Sanchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C & Castellon EA 2009 Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 69 1448-1459. (doi:10.1002/pros.20991)
147. Saporita AJ, Ai J & Wang Z 2007 The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67 509-520. (doi:10.1002/pros.20541)
148. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y et al. 2009 Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clinical Cancer Research 15 3872-3880. (doi:10.1158/1078-0432.CCR-08-1946)
149. Shaikh IA, Brown I, Schofield AC, Wahle KW & Heys SD 2008 Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 68 1635-1646. (doi:10.1002/pros.20830)
150. Singh S & Aggarwal BB 1995 Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. Journal of Biological Chemistry 270 24995-25000.
151. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A & Figg WD 2008 ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clinical Cancer Research 14 4543-4549. (doi:10.1158/1078-0432.CCR-07-4230)
152. Smith PC & Keller ET 2001 Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48 47-53. (doi:10.1002/pros.1080)
153. Solit DB, Egorin M, Kopil C, Delacruz A, Shaffer D, Slovin S, Morris M, Kelly WK, Rosen N & Scher H 2005 Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin). ASCO Annual meeting abstract. Journal of Clinical Oncology 23 (16S) abstract 3051.
154. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A & Gleave ME 2008 Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU International 102 389-397. (doi:10.1111/j.1464-410X.2008.07618.x)
155. Springate CM, Jackson JK, Gleave ME & Burt HM 2005 Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemotherapy and Pharmacology 56 239-247. (doi:10.1007/s00280-004-0997-5)
156. Srinivasan S, Kumar R, Koduru S, Chandramouli A &Damodaran C 2010 Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer. Apoptosis 15 153-161. (doi:10.1007/s10495-009-0416- 9)
157. Stephanou A & Latchman DS 2003 STAT-1: a novel regulator of apoptosis. International Journal of Experimental Pathology 84 239-244. (doi:10.1111/j.0959-9673.2003.00363.x)
158. Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F et al. 2009a Docetaxel plus oblimersen sodium (bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Annals of Oncology 20 1264-1269. (doi:10.1093/annonc/mdn784)
159. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabro F, James N et al. 2009b Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. Journal of Clinical Oncology 27 5431-5438. (doi:10.1200/JCO.2008.20.1228)
160. Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J &Hait WN 2000 Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. Journal of Clinical Investigation 105 1261-1267. (doi:10.1172/JCI9290)
161. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J & Sledge GW Jr 2001 The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Research 61 3369-3372. (Pubitemid 32695027)
162. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H & Cheng L 2004 Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clinical Cancer Research 10 5501-5507. (Pubitemid 39100488)
163. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET & Namiki M 2007 The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67 955-967. (doi:10.1002/pros.20581)
164. Talbot DC, Davies J, Callies S, Andre V, Lahn M, Ang J, De Bono JS & Ranson M 2008 First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. ASCO Annual meeting abstract. Journal of Clinical Oncology 26 (15S) abstract 3518.
165. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM et al. 1996 Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone- resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of Clinical Oncology 14 1756-1764. (Pubitemid 26185452)
166. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 351 1502-1512. (doi:10.1056/NEJMoa040720)
167. Tohnya TM, Gulley J, Arlen PM, Sparreboom A, Venitz J, Parker C, Fedenko K, Parnes H, Figg WD & Dahut WL 2006 Phase I study of lenalidomide, a novel thalidomide analog, in patients with refractory metastatic cancer. ASCO Annual meeting abstract. Journal of Clinical Oncology 24 (18S) abstract 13038.
168. Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J et al. 2004 A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clinical Cancer Research 10 5048-5057. (Pubitemid 39106850)
169. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P et al. 2008 Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. Journal of Clinical Oncology 26 5198-5203. (doi:10.1200/JCO.2008.17.2064)
170. Visa L, Pineda E, Farrus B, Codony-Servat J, Filella X, Albiol S, Martinez A, Domingo-Domench JM, Gascon P & Mellado B 2009 Correlation of serum interleukin-6 (IL-6) levels and clinical outcome in hormone-independent (HI) prostate cancer (PC) patients (PTS) treated with docetaxel. ASCO Annual meeting abstract. Journal of Clinical Oncology 27 (15S) abstract e16044.
171. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH & Keller ET 2006 Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Research 66 3087-3095. (doi:10.1158/0008-5472.CAN- 05-3447)
172. Wang H, Yu D, Agrawal S & Zhang R 2003 Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 54 194-205. (doi:10.1002/pros.10187)
173. Wilding G, Chen Y, DiPaola RP, Carducci MA & Liu G 2008 E3803: updated results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). ASCO Annual meeting abstract. Journal of Clinical Oncology 26 (15S) abstract 5070.
174. Wilson MR & Easterbrook-Smith SB 2000 Clusterin is a secreted mammalian chaperone. Trends in Biochemical Science 25 95-98. (Pubitemid 30122416)
175. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, Wilson RH, Johnston PG & Waugh DJJ 2008 Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. Journal of Pharmacology and Experimental Therapeutics 327 746-759. (doi:10.1124/jpet.108.143826)
176. Xie K 2001 Interleukin-8 and human cancer biology. Cytokine & Growth Factor Reviews 12 375-391. (Pubitemid 32851749)
177. Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L et al. 2008 The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. Journal of Biological Chemistry 283 3349-3356. (doi:10.1074/jbc.M707773200)
178. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U & Gleave ME 2005 A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Molecular Cancer Therapeutics 4 1689-1698. (doi:10.1158/1535-7163.MCT-05-0064)
179. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U & Gleave ME 2006 Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU International 97 1300-1308. (doi:10.1111/j.1464-410X.2006.06147.x)
180. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K & Igawa M 2006 Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clinical Cancer Research 12 6116-6124. (doi:10.1158/1078-0432.CCR-06-0147)
181. Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST & Parkin JD 2000 MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer and Prostatic Diseases 3 66-75. (Pubitemid 30663591)
182. Zemskova M, Sahakian E, Bashkirova S & Lilly M 2008 The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. Journal of Biological Chemistry 283 20635-20644. (doi:10.1074/jbc.M709479200)
183. Zhang Z, Li M, Wang H, Agrawal S & Zhang R 2003 Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. PNAS 100 11636-11641. (Pubitemid 37205988)
184. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R & Wang CY 2005a Clusterin inhibits apoptosis by interacting with activated Bax. Nature Cell Biology 7 909-915. (doi:10.1038/ncb1291)
185. Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, Shipley WU & Chakravarti A 2005b Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 64 293-302. (doi:10.1002/pros.20263)
186. Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, Chen Z, Wang R, Marshall FF, Chung LW et al. 2010 Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Molecular Cancer 9 9. (doi:10.1186/1476-4598-9-9)
187. Zhao X, van Steenbrugge GJ & Schroder FH 1992 Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor. Urological Research 20 193-197. (doi:10.1007/BF00299716)
188. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN et al. 2009 Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research 69 7696-7703. (doi:10.1158/0008-5472.CAN-08-4901)
189. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G &Sparreboom A 2000 Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clinical Cancer Research 6 2598-2603. (Pubitemid 30482093)
190. van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA &Verweij J 2002 Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. European Journal of Cancer 38 1090-1099.